NRG1 is expressed in multiple types of cancer cells and is implicated in therapy resistance to EGFR-targeting antibody cetuximab in CRC, RAF inhibitors in BRAF mutant melanoma, and MEK inhibitors in metastatic uveal melanoma [130]. This evidence concerns the gene BRAF and cancer.